Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hypertrophy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Candesartan; Candesartan cilexetil; Felodipine; Natriuretic Peptide, Brain

Criteria

Inclusion Criteria:

• Hypertension with diastolic blood pressure within 95-115 mm/Hg or/and systolic blood pressure within 160-200 mm/Hg

• Patients diagnosed as left ventricular hypertrophy by electrocardiogram

Exclusion Criteria:

• Secondary hypertension

• History of myocardial infarction

• Stroke within the previous 6 months